PAD4 Inhibition and DNase Anti-NET Therapy for Fibrosis and Wounds
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Fibrosis, characterized by excessive extracellular matrix deposition, impairs organ function, and NETosis, mediated by peptidylarginine deiminase 4 (PAD4), contributes to age-related organ dysfunction and delayed wound healing, particularly in diabetes.
Innovation Solution
Administration of anti-NET compounds, including PAD4 inhibitors such as Cl-amidine and DNase, to inhibit NET formation and promote wound healing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NETosis is inhibited using anti-NET compounds, then fibrosis progression is reduced and organ function is improved, but wound healing may be impaired due to reduced neutrophil defense mechanisms
Solution Approach 1:
The patent applies local quality by administering anti-NET compounds specifically to fibrotic tissues rather than systemically throughout the body. This localized approach allows inhibition of NETosis in fibrotic areas to improve organ function while maintaining normal neutrophil function in wound sites, thus avoiding impairment of wound healing processes.
Solution Approach 2:
The patent uses DNase I as an intermediary enzyme that specifically degrades extracellular DNA in NETs without affecting other cellular components. This intermediary approach selectively removes the harmful NET component (extracellular DNA) while preserving the functional integrity of neutrophils and their ability to participate in wound healing, thereby resolving the contradiction between reducing fibrosis and maintaining wound healing capacity.
2Object-generated harmful factors
If PAD4 inhibitors are used to block NET formation, then chronic inflammation is reduced, but antimicrobial defense capability may be compromised
Solution Approach 1:
The patent extracts and removes only the harmful component (extracellular DNA of NETs) from the neutrophil defense system using DNase I degradation. This extraction approach eliminates the pro-inflammatory NETs that drive chronic inflammation while leaving the intact neutrophils and their antimicrobial mechanisms functional, thus resolving the contradiction between reducing inflammation and maintaining defense capability.
Solution Approach 2:
The patent converts the harmful effect of NETs (chronic inflammation and fibrosis) into a beneficial outcome by selectively degrading their extracellular DNA component. The degraded DNA products are harmless and can even serve as signaling molecules for tissue repair, while the neutrophils remain functional for antimicrobial defense, thus transforming the harmful NETosis process into a beneficial therapeutic approach.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Reduces fibrosis progression and enhances wound healing by inhibiting NETosis, improving organ function and reducing chronic inflammation in diabetes.
Implementation Method 1
Administration of anti-NET compounds, including PAD4 inhibitors such as Cl-amidine and DNase, to inhibit NET formation
Implementation Method 2
Administration of anti-NET compounds, including PAD4 inhibitors such as Cl-amidine and DNase, to inhibit NET formation
Data Source
AI summary
Embodiments of the technology described herein are based, in part, upon the discovery that NETosis, the formation of neutrophil extracellular traps (NETs) is increased in wounds, in organ fibrosis and in subjects with diabetes. Accordingly, methods for treating wounds, fibrosis and NET associated complications in diabetes are provided. The methods comprise administrating a therapeutically effective amount of at least one anti-NET compound to a subject in need of treatment, e.g. a PAD 4 inhibitor, a DNase, a histone-degrading enzyme; an inhibitor of chromatin decondensation; an antibody against a component of a NET; an inhibitor of NET release, a protease inhibitor, or an elastase inhibitor.